Perspectives on treating hypertension.
Lowering the blood pressure to levels for which the arterial system has been designed should reduce various complications in the coronary and cerebral arteries, the heart, and the kidney. However, the antihypertensive treatment itself should not produce any significant damage. It is very likely that early modes of antihypertensive treatment did cause some biologic harm, which prevented the expected reduction in the incidence of coronary artery disease. However, the inability of these early forms of treatment to greatly improve coronary artery disease does not necessarily apply to treatments of the future.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000818:Animals; D001581:Benzothiadiazines; D005075:Biological Evolution; D001794:Blood Pressure / Q000187:drug effects*; D002561:Cerebrovascular Disorders / Q000209:etiology; D004039:Diet, Sodium-Restricted; D004198:Disease Susceptibility; D004232:Diuretics; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D008875:Middle Aged; D045283:Natriuretic Agents / Q000627:therapeutic use; D009842:Oligopeptides / Q000627:therapeutic use; D011188:Potassium / Q000378:metabolism; D051381:Rats; D012964:Sodium / Q000378:metabolism; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013722:Teprotide
D000319:Adrenergic beta-Antagonists; D001581:Benzothiadiazines; D004232:Diuretics; D045283:Natriuretic Agents; D009842:Oligopeptides; D049993:Sodium Chloride Symporter Inhibitors; D012964:Sodium; D013722:Teprotide; D011188:Potassium